New research identifies key reasons racial disparities exist in emergent stroke treatment
June 30, 2011 in CardiologyAfrican-Americans are less likely than whites to receive critical stroke treatment primarily because they do not get to a hospital soon enough for time-sensitive treatment and because of preexisting medical conditions. For patients who are eligible for treatment, no racial disparity was found.
Those are the findings of a new Georgetown University Medical Center study involving the review of almost 1,000 patient records from all seven acute care hospitals in Washington, DC. The new study will be published in the June 30th issue of American Stroke Association's Stroke.
"Our study probably can be generalized to other urban communities in the US," says Chelsea Kidwell, MD, director of the Georgetown University Stroke Center. "The good news is that the results of the study provide important information on how to improve stroke treatment care in African-Americans in the future," she says.
The researchers looked at whether patients received the best drug possible to treat the most common type of stroke, called ischemic stroke. This type of stroke is caused by a blood clot that blocks blood flow in the brain. The drug tPA, or tissue plasminogen activator, is designed to break up the clot, which can reduce the effects of a stroke and reduce permanent disability. tPA is administered intravenously at a hospital and must be given within a few hours after the patient's initial symptoms. Previous studies, however, have suggested that blacks are less likely than whites to receive tPA. Researchers set out to determine if the disparity existed in the District of Columbia and if so, what the reasons might be.
For the study, Kidwell and her colleagues reviewed 973 records from patients hospitalized with ischemic stroke at all seven Washington, DC acute care hospitals. Of the patients, 80 percent were black, and 20 percent were non-Hispanic white.
"In Washington, a predominantly black urban population, we found that blacks were a third less likely to be treated with tPA than whites," explains Kidwell. She says understanding the reasons for this disparity are critical for making change in the future.
Researchers found that blacks were more likely to arrive at a hospital after the narrow treatment window during which tPA must be administered to be effective. Even if they arrived within three hours of symptom onset, blacks were still half as likely to be treated with tPA than whites.
"A key reason why fewer blacks received tPA appears to a greater rate of pre-existing medical conditions such as uncontrolled hypertension, recent stroke or being on blood thinners," Kidwell explains. "These conditions make tPA administration unsafe."
Uncontrolled hypertension accounted for nine percent of the patients who didn't receive tPA. An additional 10 percent had a recent stroke or evidence of a prior hemorrhage.
After accounting for the differences, the researchers found that of the tPA eligible patients, the treatment rate for blacks and whites was actually similar.
"Our study not only demonstrates that there is a racial disparity in acute stroke treatment rates in this predominantly African-American urban population, but identifies two important underlying reasons: African-Americans do not get to the hospital early enough for treatment and they have a greater number of medical reasons for not receiving treatment," says Kidwell.
"Interventions designed to increase treatment in this population need to focus on culturally relevant education programs designed to address barriers specific to this population," she says.
Provided by
Georgetown University Medical Center
-
University Hospitals system-approach to stroke care increases the use of tPA therapy by 13.5-fold
Feb 11, 2011 |
not rated yet |
0
-
Use of clot busters for stroke increased from 2005 to 2009, but still low
Jun 02, 2011 |
not rated yet |
0
-
Drug may improve outcomes in mild stroke patients, save $200 million annually
Feb 09, 2011 |
not rated yet |
0
-
High blood pressure after stroke should not necessarily rule out use of clot-busting treatment
Sep 08, 2008 |
not rated yet |
0
-
Blacks less likely than whites, Hispanics to get evidence-based stroke care
Mar 22, 2010 |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (3) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Your brain on 'shrooms: fMRI elucidates neural correlates of psilocybin psychedelic state
Feb 29, 2012 |
4.9 / 5 (42) |
45
-
a numerical problem...kindly provide d solution
8 hours ago
-
energy and momentum conservation
8 hours ago
-
Uniform circular motion (centripetal acceleration & force)
10 hours ago
-
Rotational Mechanics: Sphere collision problem
16 hours ago
-
Combustion Model
16 hours ago
-
Properties of Cathode Rays
16 hours ago
- More from Physics Forums - Classical Physics
More news stories
Low vitamin D in diet increases stroke risk in Japanese-Americans
Japanese-American men who did not eat foods rich in vitamin D had a higher risk of stroke later in life, according to results of a 34-year study reported in Stroke, an American Heart Association journal.
Cardiology
4 hours ago |
not rated yet |
0
Clot buster seems to help up to 6 hours after stroke
(HealthDay) -- The largest study of its kind finds that stroke patients benefit from a clot-busting drug even six hours after a stroke, suggesting that the current recommended 4.5-hour limit could be expanded.
Cardiology
15 hours ago |
not rated yet |
0
Calcium supplements linked to significantly increased heart attack risk
Calcium supplements might increase the risk of having a heart attack, and should be "taken with caution," concludes research published in the online issue of the journal Heart.
Cardiology
May 23, 2012 |
not rated yet |
1
|
New study confirms value of cardiac output monitor
(Medical Xpress) -- A new Australian study has confirmed the accuracy of a modern non-invasive cardiac output monitor that can replace a 40-year-old standard in this field.
Cardiology
May 23, 2012 |
not rated yet |
0
Scientists turn patients' skin cells into heart muscle cells to repair their damaged hearts
For the first time scientists have succeeded in taking skin cells from heart failure patients and reprogramming them to transform into healthy, new heart muscle cells that are capable of integrating with existing heart tissue.
Cardiology
May 23, 2012 |
5 / 5 (2) |
0
|
Amino acid consumption associated with how fast cancer cells divide
For almost a century, researchers have known that cancer cells have peculiar appetites, devouring glucose in ways that normal cells do not. But glucose uptake may tell only part of cancer's metabolic story. Researchers from ...
'Personality genes' may help account for longevity
"It's in their genes" is a common refrain from scientists when asked about factors that allow centenarians to reach age 100 and beyond. Up until now, research has focused on genetic variations that offer a physiological advantage ...
Gene discovery points towards non-hormonal male contraceptive
A new type of male contraceptive could be created thanks to the discovery of a key gene essential for sperm development.
Thioridazine kills cancer stem cells in human while avoiding toxic side-effects of conventional cancer treatments
A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments.
Cyber exercise partners help you go the distance: Motivation gains can double
A new study testing the benefits of a virtual exercise partner shows the presence of a moderately more capable cycling partner can significantly boost the motivation by as much as 100 percent ...
Brentuximab vedotin effective in large-cell lymphoma
(HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete ...